Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab +/- Relatlimab in Advanced Cutaneous Squamous Cell Carcinoma
NCT04204837Phase 2Recruiting
- Sponsor
- Salzburger Landeskliniken
- Start
- Mar 2017
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, relatlimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Salzburger Landeskliniken. Started Mar 2017; status: recruiting.
02
Drugs
nivolumabrelatlimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04204837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04204837.